Literature DB >> 15519903

Murine models for the study of congestive heart failure: Implications for understanding molecular mechanisms and for drug discovery.

Qing-Dong Wang1, Mohammad Bohlooly-Y, Mohammad Bohlooly, Per-Ove Sjöquist.   

Abstract

Congestive heart failure (CHF) is a complex illness of diverse aetiology. Despite the current multiple therapies, the prognosis for CHF patients remains poor, and new therapeutic targets need to be identified. With the advent of the genetic era, the mouse has become an increasingly valuable animal species in experimental CHF research. A large number of murine models of cardiac hypertrophy and CHF have been created by genetic engineering. Meanwhile, traditional CHF models created by coronary artery ligation, cardiac pressure, or volume overload have been adapted to mice. The present review categorizes and highlights the value of these murine models of cardiac hypertrophy and CHF. These models, combined with sophisticated physiological measurements of cardiac haemodynamics, are expected to yield more and valuable information regarding the molecular mechanisms of CHF and aid in the discovery of novel therapeutic targets.

Entities:  

Mesh:

Year:  2004        PMID: 15519903     DOI: 10.1016/j.vascn.2004.05.005

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  12 in total

Review 1.  Energetics of small hearts.

Authors:  W J van der Laarse
Journal:  J Physiol       Date:  2006-03-16       Impact factor: 5.182

Review 2.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

3.  Ischemic cardiomyopathy following seizure induction by domoic Acid.

Authors:  Alexandra Vranyac-Tramoundanas; Joanne C Harrison; Punam M Sawant; D Steven Kerr; Ivan A Sammut
Journal:  Am J Pathol       Date:  2011-05-14       Impact factor: 4.307

4.  Histopathological study of time course changes in inter-renal aortic banding-induced left ventricular hypertrophy of mice.

Authors:  Hiroyuki Higashiyama; Masaki Sugai; Hirotaka Inoue; Kaori Mizuyachi; Hiroshi Kushida; Satoshi Asano; Mine Kinoshita
Journal:  Int J Exp Pathol       Date:  2007-02       Impact factor: 1.925

Review 5.  Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research.

Authors:  Vikrant Rai; Poonam Sharma; Swati Agrawal; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2016-10-20       Impact factor: 3.396

6.  Role of diastolic properties in the transition to failure in a mouse model of the cardiac dilatation.

Authors:  Peter N Costandi; Lawrence R Frank; Andrew D McCulloch; Jeffrey H Omens
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-07-21       Impact factor: 4.733

Review 7.  Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets.

Authors:  Jianglong Hou; Y James Kang
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

8.  Partial nephrectomy as a model for uremic cardiomyopathy in the mouse.

Authors:  David J Kennedy; Jihad Elkareh; Amjad Shidyak; Anna P Shapiro; Sleiman Smaili; Krishna Mutgi; Shalini Gupta; Jiang Tian; Eric Morgan; Samer Khouri; Christopher J Cooper; Sankaridrug M Periyasamy; Zijian Xie; Deepak Malhotra; Olga V Fedorova; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Am J Physiol Renal Physiol       Date:  2007-11-21

9.  High-resolution longitudinal MRI of the transition to heart failure.

Authors:  Peter N Costandi; Andrew D McCulloch; Jeffrey H Omens; Lawrence R Frank
Journal:  Magn Reson Med       Date:  2007-04       Impact factor: 4.668

10.  Cardiac Myocyte De Novo DNA Methyltransferases 3a/3b Are Dispensable for Cardiac Function and Remodeling after Chronic Pressure Overload in Mice.

Authors:  Thomas G Nührenberg; Nils Hammann; Tilman Schnick; Sebastian Preißl; Anika Witten; Monika Stoll; Ralf Gilsbach; Franz-Josef Neumann; Lutz Hein
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.